C12N 2750/14134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2750/14134 (Use of virus or viral component as vaccine) appears on 27 US grants and 59 published applications in this corpus.
Search patents in C12N- Granted patents
- 27
- Published applications
- 59
- Assignees
- 47
- Inventors
- 148
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 1 |
| 2017 | 1 | 3 |
| 2018 | 2 | 3 |
| 2019 | 1 | 2 |
| 2020 | 1 | 2 |
| 2021 | 2 | 8 |
| 2022 | 4 | 11 |
| 2023 | 4 | 8 |
| 2024 | 5 | 9 |
| 2025 | 4 | 3 |
| 2026 | 3 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions and methods for multiplexed tumor vaccination with endogenous gene activation14 Jul 2026US 12,678,493 B2Yale University
- Composition for immune tolerance induction and use in gene therapy2 Jun 2026US 12,642,866 B2The Research Foundation for The State University of New York
- AAV capsid chimeric antigen receptors and uses thereof26 May 2026US 12,637,497 B2University of Massachusetts
- Canine parvovirus (CPV) nanobody CPV-VHH-H1 and use thereof29 Jul 2025US 12,371,476 B2Institute of Animal Sciences of Caas
- Phagemid vector17 Jun 2025US 12,331,308 B2Imperial College Innovations Limited
- Nannochloropsis-producing viruses and methods and compositions for making the same1 Oct 2026US 2026/0297502 A1Insmed Incorporated
- Neddylation-activating enzyme inhibitors as viral sensitizers and uses thereof15 Jan 2026US 2026/0015592 A1Ottawa Hospital Research Institute
- Immune tolerance induction to viral capsids20 Nov 2025US 2025/0352626 A1University of Florida Research Foundation, Inc.
- Immune enhancement and infectious disease treatment17 Jul 2025US 2025/0228928 A1Spark Therapeutics, Inc.
- Methods of making and using universal centralized influenza vaccine genes30 Jan 2025US 2025/0032601 A1NUtech Ventures
Most cited
By later US patents
- Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies22US 10,179,176 B2The Board of Trustees of the Leland Stanford Junior University · 2019
- Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies18US 10,532,111 B2The Board of Trustees of the Leland Stanford Junior University · 2020
- Bocaparvovirus small noncoding RNA and uses thereof6US 11,142,775 B2University of Iowa Research Foundation · 2021
- Adeno-associated virus with site-directed mutagenesis and site-directed modification and preparation method and application thereof3US 10,087,217 B2Peking University · 2018
- Prokaryotic-eukaryotic hybrid viral vector for delivery of large cargos of genes and proteins into human cells2US 11,155,835 B2The Catholic University of America · 2021